Repotrectinib

{
  "id": "MLC-T-ONC-007352",
  "term": "Repotrectinib",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used to treat adults with non-small cell lung cancer that has spread and has an abnormal ROS1 gene and adults and children aged 12 years and older with certain types of solid tumors that have an NTRK gene fusion. It is also being studied in the treatment of other types of cancer. Repotrectinib blocks certain proteins involved in cell signaling and cell growth. Blocking these proteins may help keep cancer cells from growing. Repotrectinib is a type of kinase inhibitor. Also called Augtyro.",
    "An orally available inhibitor of multiple kinases, including the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), the neurotrophic tyrosine receptor kinase (NTRK) types 1, 2 and 3, the proto-oncogene SRC, and focal adhesion kinase (FAK), with potential antineoplastic activity. Upon oral administration, repotrectinib binds to and inhibits wild-type, point mutants and fusion proteins of ALK, ROS1, NTRK1-3, SRC, FAK and, to a lesser extent, other kinases. Inhibition of these kinases leads to the disruption of downstream signaling pathways and the inhibition of cell growth of tumors in which these kinases are overexpressed, rearranged or mutated."
  ],
  "synonyms": [
    "Augtyro",
    "ALK/ROS1/NTRK/SRC/FAK multikinase inhibitor TPX-0005",
    "multikinase inhibitor TPX-0005",
    "multi-kinase inhibitor TPX-0005"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/repotrectinib/"
}